SINOTHERAPEUTICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.1 CNY | +2.02% |
|
+1.90% | -17.12% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7,593 | 4,978 |
| Enterprise Value (EV) 1 | 6,832 | 4,229 |
| P/E ratio | 76.1 x | 84.5 x |
| Yield | 0.37% | 0.37% |
| Capitalization / Revenue | 30.7 x | 16.6 x |
| EV / Revenue | 27.6 x | 14.1 x |
| EV / EBITDA | 91.3 x | 69.3 x |
| EV / FCF | -35,142,394 x | -98,669,266 x |
| FCF Yield | -0% | -0% |
| Price to Book | 6.45 x | 4.11 x |
| Nbr of stocks (in thousands) | 453,340 | 453,340 |
| Reference price 2 | 16.75 | 10.98 |
| Announcement Date | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 60.93 | 141.3 | 316.7 | 315.5 | 247.6 | 299.9 |
| EBITDA 1 | -42.35 | -8.042 | 127 | 111.1 | 74.79 | 60.98 |
| EBIT 1 | -53.23 | -19.35 | 114.3 | 95.1 | 58.21 | 44.3 |
| Operating Margin | -87.36% | -13.7% | 36.1% | 30.14% | 23.51% | 14.77% |
| Earnings before Tax (EBT) 1 | -46.55 | 1.482 | 134.5 | 149 | 97.48 | 65.99 |
| Net income 1 | -37.48 | 4.535 | 116.5 | 134.9 | 92.94 | 61.07 |
| Net margin | -61.52% | 3.21% | 36.79% | 42.77% | 37.54% | 20.37% |
| EPS 2 | -0.1050 | 0.0100 | 0.2856 | 0.3300 | 0.2200 | 0.1300 |
| Free Cash Flow | - | 13.26 | 121 | 30.86 | -194.4 | -42.86 |
| FCF margin | - | 9.38% | 38.19% | 9.78% | -78.53% | -14.29% |
| FCF Conversion (EBITDA) | - | - | 95.27% | 27.78% | - | - |
| FCF Conversion (Net income) | - | 292.27% | 103.79% | 22.87% | - | - |
| Dividend per Share | - | - | - | - | 0.0620 | 0.0410 |
| Announcement Date | 5/20/21 | 5/20/21 | 5/20/21 | 8/7/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 183 | 258 | 434 | 507 | 762 | 749 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 13.3 | 121 | 30.9 | -194 | -42.9 |
| ROE (net income / shareholders' equity) | - | 1.1% | 23.6% | 21.3% | 9.87% | 5.12% |
| ROA (Net income/ Total Assets) | - | -2.55% | 11.4% | 7.41% | 3.31% | 2.06% |
| Assets 1 | - | -178.2 | 1,021 | 1,821 | 2,808 | 2,971 |
| Book Value Per Share 2 | 1.110 | 1.040 | 1.380 | 1.730 | 2.600 | 2.670 |
| Cash Flow per Share 2 | 0.5100 | 0.6300 | 1.060 | 1.250 | 1.680 | 1.420 |
| Capex 1 | 9.6 | 23.7 | 38.3 | 16 | 176 | 39 |
| Capex / Sales | 15.76% | 16.76% | 12.1% | 5.07% | 71.23% | 12.99% |
| Announcement Date | 5/20/21 | 5/20/21 | 5/20/21 | 8/7/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.12% | 553M | |
| +15.91% | 42.02B | |
| +22.40% | 21.66B | |
| +18.48% | 15.09B | |
| +16.12% | 14.21B | |
| +45.12% | 12.37B | |
| -0.05% | 6.79B | |
| -9.58% | 6.59B | |
| -8.87% | 5.73B | |
| +14.18% | 5.56B |
- Stock Market
- Equities
- 688247 Stock
- Financials Sinotherapeutics Inc.
